Friday 12 March | |
Autins Group PLC | AGM |
Monday 15 March | |
Hardide PLC | AGM |
Jupiter UK Growth Investment Trust PLC | GM re liquidation |
Tuesday 16 March | |
Blackrock Energy & Resources Income Trust PLC | AGM |
Blue Prism Group PLC | AGM |
Plus500 Ltd | EGM |
Starvest PLC | AGM |
Wednesday 17 March | |
Aura Energy Ltd | AGM |
Safestore Holdings PLC | AGM |
Scapa Group plc | GM re cash offer by AMS Holdco 2 Ltd |
Thursday 18 March | |
4D Pharma PLC | GM re Longevity merger |
Amino Technologies PLC | AGM |
BigDish PLC | AGM |
CML Microsystems PLC | GM re return of capital |
Drum Income Plus REIT PLC | AGM |
Idox PLC | AGM |
Impax Asset Management Group PLC | AGM |
Shield Therapeutics PLC | GM re share placing |
Signature Aviation PLC | GM re acquisition |
Sureserve Group PLC | AGM |
Tullow Oil PLC | GM re disposals in Equatorial Guinea and Gabon |
Copyright 2021 Alliance News Limited. All Rights Reserved. |
IN BRIEF: 4D Pharma rises as asthma drug moves on to part B of trial
4D Pharma PLC - Leeds, England-based pharmaceutical company - Says part A of the phase I/II trial of MRx-4DP0004 for the treatment of asthma showed that a greater amount of patients receiving the drug than those receiving placebo experienced a reduction in asthma control questionnaire scores. Reports that a greater proportion of the MRx-4DP0004 group than the placebo group experienced a reduction in the total weekly use of rescue medication at all time points. Adds that 50% of patients receiving the drug experienced "clinically meaningful" improvements in asthma quality of life questionnaire scores. Says MRx-4DP0004 is progressing to part B of the trial. Plans to enrol asthma patients with more symptomatic disease. Expects this to give a greater scope for treatment effects to be observed.
Read more